Skip to main content

Advertisement

Cancer risk in immune-mediated inflammatory diseases (IMID)

Article metrics

Abstract

Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but inflammatory cells also mediate an immune response against the tumor and immunosuppression is known to increase the risk for certain tumors.

This article reviews current literature on the role of inflammation in cancer and the cancer risk in immune-mediated inflammatory diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors.

Overall cancer incidence and mortality risk are similar to the general population in inflammatory bowel disease (IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce.

This review provides clinicians with a solid background to help them in making decisions about treatment of immune-mediated diseases in patients with a tumor history.

This article is related to another review article in Molecular Cancer: http://www.molecular-cancer.com/content/12/1/86.

Introduction

Immune-mediated inflammatory diseases (IMIDs) are a group of chronic and highly disabling diseases involving inappropriate or excessive immune responses caused or accompanied by cytokine dysregulation and acute or chronic inflammation [1]. This includes a wide variety of illnesses, such as Crohn’s disease (CD), ulcerative colitis (UC), psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). IMIDs are fairly common, affecting an estimated 5% to 7% of the population in Western countries. Treatment of IMIDs focuses on the rapid control of inflammation, prevention of tissue damage, and where possible, long-term remission of the disease. This is achieved using corticosteroids, immunosuppressants, and “biologicals”, especially those targeting tumor necrosis factor (TNF).

Because immunosurveillance is thought to help suppress the development of cancer, there are concerns that immunotherapies might increase cancer risk in patients with IMIDs. Furthermore, inflammation is known to have both pro- and anti-tumorigenic effects, and cancer-related inflammation is now considered the seventh hallmark of cancer [2].

In this article, we discuss the current state of knowledge concerning the relationship between IMIDs and cancer. This information should help clinicians decide about the safety of giving immunosuppressive therapies to IMID patients with a history of tumors.

Dual relationship between inflammation and cancer

Inflammation can occur in response to dietary or environmental factors, infection, and autoimmune diseases including IMIDs. Inflammatory cells are present in most, if not all, solid tumors [3]. Tumor-associated macrophages can comprise up to as much as half of the mass of a solid tumor [4]. These cells promote tumor cell survival, proliferation, and dissemination, and a high level of them is associated with a poor prognosis. Tumor-associated inflammatory cells appear to be actively recruited, possibly as part of an anti-tumor response, but this inflammatory response may be usurped by the tumor to promote tumorigenesis [3].

Anti-tumorigenic effects of inflammation

Activation of inflammatory cells as part of an immune response to eliminate mutant cells, a process called immunosurveillance, was originally suggested by Ehrlich and later formalized by Burnet and Thomas [5]. Aberrant proteins or peptide-MHC complexes on the surfaces of transformed or malignant cells are recognized and targeted for elimination by the immune system. Evidence that the immune system recognizes and eliminates tumor cells was originally obtained in mice, but this is also supported by several lines of clinical evidence: cancer incidence is increased in transplant patients treated with immunosuppressants; cancer patients develop immune responses to tumors; immune responses in tumors correlate with improved prognosis in colorectal cancer; survival positively correlates with the presence of tumor-infiltrating lymphocytes, CD8+ T cells, and natural killer cells in various cancers; higher natural cytotoxic activity of peripheral blood lymphocytes correlates with a reduced cancer risk [68].

Murine studies found that tumors formed in the absence of an intact immune system are more immunogenic in wild-type mice than those formed in the presence of an intact immune system [913]. In other words, the immune response eliminated the more immunogenic cells and selected less immunogenic cells, a process that Dunn and colleagues refer to as “immunologic sculpting” or “immunoediting” [7]. Immunoediting is composed of three phases: “elimination”, “equilibrium”, and “escape”. The initial phase of an immune response to a tumor, elimination, is the same as immunosurveillance and results in destruction of (part of) the tumor cells [7]. Dunn and colleagues envision that the tumor thereafter remains in equilibrium with the immune system, wherein selection pressure continues but is unable to eliminate the tumor. In this equilibrium phase, some tumor cells are eliminated and others, including new variants, survive. In the final escape phase, the selected tumor cell variants have become resistant to elimination by the immune system.

Efficient inhibition of tumor growth was recently shown to involve not only defined cell death and clearance mechanisms by CD8+ cytotoxic T lymphocytes and natural killer cells, but also the induction of tumor cell senescence by interferon-γ and TNF producing CD4+ T-helper 1 cells. In addition, T-helper 1 immunity can also induce anti-angiogenic chemokines that protect against cancer [14].

Pro-tumorigenic effects of inflammation

A wide range of studies indicate that inflammation also contributes more directly to tumorigenesis [15]. Nearly one in five cancers is linked to infections: e.g. Helicobacter pylori and Hepatitis C virus infections eventually lead to gastric and liver cancers, respectively [16, 17]. Also, many cancers are associated with persistent inflammation due to environmental factors or autoimmune reactions: e.g. lung cancer is associated with asbestosis and smoking, colon cancer with inflammatory bowel disease (IBD), and lymphoma with celiac disease [8, 17]. Furthermore, numerous experimental and epidemiologic studies, along with randomized clinical trials showed that long-term daily use of the nonsteroidal anti-inflammatory drug aspirin reduced the incidence of several cancers, especially those of the gastrointestinal tract [1821]. The mechanism of action of the chemopreventive and anticancer effects of aspirin is not fully understood, but it has been attributed to its anti-inflammatory effects, specifically inhibition of prostaglandin-endoperoxide synthase 2 (formerly named cyclooxygenase 2), which is the rate-limiting step for the conversion of arachidonic acid to prostaglandins. Because aspirin can cause stomach upset and dangerous internal bleeding, its use as anticancer drug for the general population is still under debate [22]. Together, these findings suggest that when inflammation becomes persistent or dysfunctional, it can promote tumor growth, as inflammatory cells, normally recruited to control damage, are diverted by the tumor for pro-tumorigenic purposes [3, 23].

How chronic inflammation increases cancer risk is beginning to come into focus [3, 15]. Chronic inflammation can initiate tumors by directly causing DNA changes or making cells more susceptible to mutagens. In addition, inflammation can act as a tumor promoter. Inflammatory mediators, including cytokines like TNF, interleukin (IL)-1, and IL-6, growth factors, chemokines, and proteases produced by tumor-associated lymphocytes and macrophages can enhance tumor cell growth and metastasis by promoting their survival, proliferation, migration to and invasion of other tissues. Tumor-associated macrophages release inflammatory mediators that stimulate tumor angiogenesis and lymphangiogenesis [4, 23], and produce cytokines, including transforming growth factor (TGF) β and IL-10, that can directly suppress immune responses [24]. Also, myeloid-derived suppressive cells, which accumulate in infections, inflammatory and autoimmune diseases, and cancer, can inhibit tumor immunosurveillance and suppress natural killer cells [25].

At the molecular level, the transcription factor NF-κB appears to be a key connecting element between inflammation and cancer [26]. NF-κB is a central intracellular transducer of inflammatory signals [27], integrating signals from a variety of environmental changes, including infection, tissue damage and autoimmunity [26]. Several proinflammatory cytokines such as TNF and IL-1 are potent activators of NF-κB, which regulates the transcription of a variety of inflammatory genes, including TNF and IL-1 themselves, thus further amplifying the proinflammatory signal [2628]. Not surprisingly, NF-κB is activated in many inflammatory diseases, and inhibitors of NF-κB have beneficial effects in mouse models of inflammation [29]. Additionally, mutant forms of NF-κB, NF-κB inhibitor proteins such as IκBα and A20, or upstream signaling components that feed into NF-κB, are found in many cancers [30]. NF-κB activation is thought to act as a tumor promoter by enhancing tumor cell survival and proliferation and helps convert tumor-associated macrophages to a tumor-promoting phenotype [26]. Despite these pro-oncogenic roles, drugs specifically targeting NF-κB have had limited success in treating cancer, although ubiquitin-proteasome targeting drugs such as bortezomib and carfilzomib, which act in part by preventing NF-κB activation, have been successfully approved for clinical application while some other promising candidates are currently under clinical trials [31].

NF-κB also regulates the expression of IL-6, a multifunctional cytokine that plays important roles in immune responses, cell survival and proliferation. Mouse studies demonstrated that IL-6 is important for both tumor development and growth in colitis associated cancer, with IL-6 promoting both proliferation and survival of intestinal epithelial cells via the activation of the transcription factor STAT3 [32, 33]. Although in many cancers STAT3 is not directly activated by oncogenic mutations, it exerts critical oncogenic functions in both cancer and immune cells within the microenvironment [34]. More recently, mouse studies also demonstrated a critical role for IL-23 and its downstream cytokines IL-17 and IL-22 in the development of colitis-associated cancer [35], increasing the number of cytokines that link inflammation with the development of cancer.

IMIDs and Cancer Risk

IMIDs are characterized by severe inflammation [1]. Given the molecular and cellular links between inflammation and cancer, it is not surprising that many IMIDs are associated with an increased risk of cancer (Table 1), although confounding effects of treatment are hard to eliminate.

Table 1 Examples of IMIDs associated with increased risks for cancer

Rheumatoid arthritis

Although its triggers are unknown, RA is considered the archetypal IMID in which autoimmunity induces the production of the pro-inflammatory cytokines TNF, IL-1, and IL-6, triggering the production of degradative enzymes that destroy the joints and further stimulate the T cell response [1].

Two Swedish population-based studies found that patients with RA are at an approximately two-fold increased risk for lymphoma and leukemia, a 20% to 50% increased risk for respiratory tract cancer, and a 70% increased risk for non-melanoma skin cancers (NMSC), but at decreased risk for breast and colorectal cancer [30, 32]. A meta-analysis including 21 publications confirmed the increased risk for lymphoma and lung cancer and decreased risk for colorectal and breast cancer in RA [33]. Increased lymphoma risk is limited, however, to the subset of RA patients with longstanding and very severe disease [34].

Inflammatory bowel diseases

Crohn’s disease and ulcerative colitis represent the two principal forms of IBD [35]. Both are chronic inflammatory diseases apparently caused by an inappropriate immune response, probably to a gut antigen that is normally suppressed [1]. Both diseases are characterized by severe gastrointestinal inflammation, although they also have systemic manifestations affecting the skin, eyes, joints, liver, hepatobiliary system [1, 67].

Overall cancer incidence rates are increased in CD, but similar to the general population in UC [68]. Meta-analyses indicate that patients with CD are at increased risk for colorectal and fistula cancer and for cancer of the small bowel, upper gastrointestinal tract, lung, bladder and skin [4244]. A Swedish registry study of more than 27,000 CD patients hospitalized between 1964 and 2004 found elevated risks for liver, pancreatic, prostate, testicular, and kidney cancers, nonthyroid endocrine tumors, and leukemia [45].

Patients with UC have an increased risk of colorectal carcinoma, liver-biliary cancer, and leukemia but a reduced risk of pulmonary cancer [42, 66]. The risk of colorectal cancer in UC is further elevated in patients with dysplasia and ongoing mucosal inflammation [6971].

Psoriasis

Psoriasis is a chronic inflammatory skin disease characterized by circumscribed, erythemato-squamous plaques with adherent scales [72]. Psoriasis appears to be driven by a dysregulation of the innate immune system mediated by IFN-α, although several other inflammatory mediators, including TNF, are also involved. Psoriasis may be associated with systemic manifestations, including an increased risk for metabolic syndrome, cardiovascular disease and systemic inflammation similar to that observed in RA.

Several studies from the pre-biologics era implicated an increased risk for lymphoma, NMSC and cancers related to alcohol and smoking in psoriasis patients [48]. Cancer risk seems to be higher in patients with severe psoriasis, which raises the question whether this is caused by chronic inflammation or by the systemic treatments more often used in severe psoriasis [49, 73].

The Iowa Women’s Health Study, which included more than 32,000 women, found a significant association only between colon cancer and psoriasis when disease incidence was adjusted for smoking, body mass index, education, physical therapy, and use of hormone therapy [47]. Other studies suggest an increased risk for cancer of the bladder, kidney, oropharynx/larynx, esophagus, stomach, liver/gallbladder, vulva, breast, and pancreas and for leukemia, non-Hodgkin’s lymphoma, and NMSC [4855]; however, these studies did not control for environmental factors such as alcohol and smoking. Although concern has been raised that psoriasis treatment with PUVA (psoralen + ultraviolet light), methotrexate, or cyclosporine can increase cancer risk [74, 75]; the most recent studies have shown that these treatments are not associated with an increased risk [50, 76, 77].

Very recently, a systematic literature review with meta-analysis was performed on the risk of cancer in psoriasis [56], accompanied by evidence-based recommendations [57]. Together, the authors concluded that there is a slightly increased risk of some cancers in patients with psoriasis (upper aero-digestive tract, liver, lung, pancreatic and urinary tract cancers), that the highest increased risk is for skin carcinoma, that there is no increased risk of melanoma and that regarding lymphoma, misdiagnosis of primary skin lymphoma as psoriasis might have overestimated the risk.

Systemic Lupus Erythematosus (SLE)

SLE is another chronic inflammatory disease triggered by an autoimmune reaction and mediated by inflammatory cytokines, especially TNF, IL-1 and type 1 interferons [78]. SLE can affect almost any tissue and is most often characterized by fatigue coupled with musculoskeletal, skin, pulmonary, cardiac, gastrointestinal, renal, neuropsychiatric, or reproductive manifestations [79]. SLE is associated with an increased risk of hematological malignancies, including non-Hodgkin’s lymphoma, and cancers of the vagina/vulva/cervix, nasopharynx, and kidney [6062], but a decreased risk of breast, ovarian, and endometrial cancer [80].

IMID treatments and cancer risk

Risk of cancer associated with immune suppression: transplantation as a model

Treatment of IMIDs focuses on inhibiting inflammation by suppressing the activity and proliferation of immune cells and the cytokine production involved in innate and adaptive immune responses [81]. Before the advent of biologics, this could only be accomplished with immunosuppressant drugs. However, experience in transplant patients indicates that these drugs increase the risk of skin cancer, especially NMSC, and the risk of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder [82]. This effect of immunosuppressants provides support for the immunosurveillance hypothesis [5, 83, 84].

Immune modulators

Thiopurines

The thiopurines azathioprine, 6-thioguanine, and 6-mercaptopurine are immunosuppressive drugs commonly used for the treatment of autoimmune diseases, for the prevention of transplant rejection and the treatment of lymphoproliferative disorders [85]. Thiopurines act in several ways to interfere with lymphocyte proliferation. Accumulating evidence shows that they increase the cancer risk in IMID patients. IBD patients treated with thiopurines have an increased risk for NMSC and lymphoma [86, 87].

A 2005 meta-analysis of cohort studies found that treatment of IBD with azathioprine or 6-MP increased the risk of lymphoma (RR = 4.2), although it was not clear whether the increased risk was due to the medications, the severity of the underlying disease, or a combination of both [88]. This conclusion was supported by a French observational study of 19,486 IBD patients followed up for a median of 35 months, which found an increased risk of lymphoproliferative disorders in patients receiving thiopurines compared to those who had never received them (HR = 5.28) [86]. In addition, two retrospective analyses reported an increase in NMSCs associated with IBD treatment (adjusted OR = 4.3 and OR = 5.0, respectively) [87, 89].

Cyclosporine

Cyclosporine is a calcineurin inhibitor that inhibits inflammation by blocking IL-2 production by activated CD4+ T cells [75]. In transplant patients, cyclosporine increases the risk of lymphoma, internal malignancies, and skin cancers [75]. A 2003 report found that in patients with psoriasis, cyclosporine increases the risk of skin cancer 6-fold [90]. The risk increased with treatment duration over 2 years and prior phototherapy. A more recent systematic review found that cyclosporine significantly increases the risk for NMSC in RA [91].

Methotrexate

Methotrexate is a folic acid analog that suppresses cell proliferation by inhibiting DNA synthesis [75]. Melanoma and Epstein-Barr virus-associated lymphomas in psoriasis patients taking methotrexate have been reported [92]. However, a Canadian observational study including 23,810 patients with RA did not find an increased risk for hematologic malignancies in patients treated with methotrexate [92]. This was also found in a 2009 meta-analysis by Salliot and van der Heijde, which reported no increase in the risk of lymphoma or malignancies in RA patients treated with methotrexate [93]. However, a 2010 systematic review by Krathen et al. suggested that methotrexate in RA may increase the risk of malignant melanoma, and double the risk for NMSC when combined with anti-TNFs; in patients with psoriasis methotrexate increased the risk of NMSC [94].

Cyclophosphamide

Cyclophosphamide suppresses immune function by inhibiting lymphocyte proliferation [95]. A Canadian observational study including 23,810 RA patients reported an increased risk of hematologic malignancies (unadjusted OR = 2.21) in patients treated with cyclophosphamide [92]. Cyclophosphamide is known to increase bladder cancer risk, and patients who have received this drug should be monitored regularly for microscopic hematuria [96].

Biologics Targeting TNF

TNF, as its name implies, was discovered as a serum factor from lipopolysaccharide-treated mice that causes tumor necrosis [97], and was originally intensively studied because of its potential use as anti-tumor agent [98]. However, initial enthusiasm about its clinical use as anti-tumor agent was curbed due to significant toxicities and lack of efficacy of systemic treatment. Clinical use of TNF for cancer treatment is therefore limited to the setting of hyperthermic isolated limb perfusion for the regional treatment of locally advanced soft tissue sarcomas, metastatic melanomas and other irresectable tumors to avoid limb amputation [99]. Moreover, a paradoxical tumor-promoting role of TNF became apparent, which may reflect the role of TNF as a key pro-inflammatory mediator and the tumor-promoting role of inflammation [100]. TNF is a key mediator of inflammation, which is barely detectable in circulation under normal conditions, but is produced by macrophages, activated T cells, natural killer cells, mast cells, and stromal cells during innate or adaptive immune responses [101, 102].

TNF acts on multiple cell types by binding to specific cell surface receptors that activate multiple signaling pathways that culminate in the activation of MAP kinase, NF-κB and other transcription factors. At high doses, TNF causes the death of tumor blood vessels, although at lower doses, it can act as a tumor promoter and enhancer of metastasis [16]. Furthermore, certain polymorphisms in the TNF gene are associated with hepatocellular cancer [103106], non-Hodgkin’s lymphoma [107], breast cancer [108], and gastric cancer [109].

TNF is an important mediator of the dysregulated immune and inflammatory function in IMIDs. Drugs that target TNF are the most widely used biologics for treating IMIDs, with five drugs currently approved for clinical treatment of IMIDs (Table 2) [110]. Although anti-TNF therapy is used in different IMIDs, not all anti-TNF agents have the same efficacy in all IMIDs [111].

Table 2 Biologics used in the treatment of IMIDs

Studies on the effect of TNF-blockers on the incidence of malignancy began to appear in the late 1990s. Bickston et al. reported the occurrence of lymphoma after infliximab treatment in patients with CD in 1999 [112]. Other individual reports of lymphoproliferative diseases in patients treated with infliximab or etanercept followed soon thereafter [113115]. A large prospective observational study including 18,572 patients from the US National Data Bank for Rheumatic Diseases found a 2.9-fold increase in the incidence of lymphoma in patients treated with etanercept or infliximab [116]. Updates three years later from this same database found the contrary – that infliximab and etanercept, after a median exposure of three years, were not associated with a risk of lymphoma in patients with RA [117, 118]. Two additional observational studies reported that anti-TNF-biologics do not increase the risk of solid cancer, lymphoma or leukemia [30, 32].

Thus, while some of the studies suggested a link between the use of anti-TNF biologics and cancer, others did not. Interpretation and reconciliation of these different findings is difficult because randomized clinical trials are usually too small or brief to obtain sufficient data to accurately determine the effects of a treatment on cancer and because most observational studies usually lack adequate control groups. Meta-analyses have therefore been performed on pooled data from multiple randomized clinical studies or prospective observational studies to better assess the risks of cancer associated with the treatment of IMIDs by biologics (Table 3).

Table 3 Meta-analyses on cancer risks associated with the use of biologics to treat IMIDs

An initial meta-analysis published in 2006 by Bongartz et al. [119] reported a 3.3-fold dose-dependent increase in malignancies associated with infliximab in RA patients. A 2011 meta-analysis by Mariette et al. [124] analyzing data from 21 prospective observational studies on anti-TNF biologics in RA found that although anti-TNF biologics are not associated with an increase in malignancies, especially lymphoma, they are associated with an increase in the risk of skin cancer, including melanoma.

Meta-analyses of randomized clinical trials, however, found that the treatment of RA with anti-TNF biologics [121, 126, 129] or biologics overall [128] does not significantly increase the risk for any type of cancer in RA patients An important limitation of the RCT data in these studies, however, is the shortness of the follow-up period of the included studies in comparison with the latency period for emergence of cancer.

An integrated analysis of three patient databases found that the risk of malignancy in RA patients treated with anti-TNF biologics does not increase with time [130].

The risk for cancer for individual anti-TNF biologics other than infliximab has been assessed in a few studies. An observational in 2004 found an increased risk of lymphoma associated with etanercept therapy in RA [116], this was not supported by their 2007 updates from the same observational database, although they did find an increased risk of skin cancer [117, 118]. A meta-analysis of randomized clinical trials from 2009 found that the use of etanercept for 12 weeks or more in patients with RA was associated with a non-significant increase in the incidence of cancer [122]. Also, a 2010 report found that the use of golimumab at the FDA-approved dose to treat RA was not associated with a difference in the rate of cancer rate [131].

A prospective observational study in France by Mariette et al. [132] found that patients receiving adalimumab or infliximab have a higher risk for lymphoma than those treated with etanercept and that exposure to adalimumab or infliximab versus etanercept was an independent risk factor for lymphoma. The 2011 meta-analysis by Askling et al. [126] did not find differences between the anti-TNF antibodies adalimumab, etanercept, and infliximab, although they suggest that this may have been due to differences in statistical precision or in baseline cancer risk between the various studies.

Few studies have examined the risk of cancer associated with the use of anti-TNF biologics in IMIDs other than RA. A 2008 meta-analysis of randomized clinical trials by Peyrin-Biroulet et al. reported that the treatment of CD by anti-TNF biologics does not increase the risk for cancer [120]. However, a more recent meta-analysis of randomized clinical trials by Siegel et al. found that treatment of CD with anti-TNF biologics in combination with immunomodulators is associated with an increased risk of non-Hodgkin’s lymphoma [123]. Analysis of data from the FDA Adverse Event Reporting System (AERS) showed that treatment with a combination of thiopurines and TNF inhibitors, but not with TNF inhibitors alone is associated with increased risk of non-Hodgkin lymphoma in IBD patients [133]. Also, a meta-analysis of randomized clinical trials in plaque psoriasis and psoriatic arthritis found that short-term anti-TNF biologic use is not associated with a significant increased risk of cancer [125].

Biologics targeting molecules other than TNF

Alefacept

Alefacept is a human fusion protein of the CD2-binding region of LFA-3 and the CH2 and CH3 domains of IgG1. It inhibits T cell activation and induces apoptosis of memory T cells and has been approved for the treatment of psoriasis [134]. Very little information is available on the risk of cancer with alefacept, although an integrated analysis of data from 13 clinical trials including 1869 patients found that this agent does not cause a dose-dependent increase in the incidence of malignancy [135].

Rituximab

Rituximab is a chimeric monoclonal antibody against the protein CD20 that induces B cell killing and has been approved for the treatment of RA refractory to anti-TNF treatment [136]. Few data are available on whether rituximab use in RA patients affects the risk of cancer, although a recent analysis of 186 patients followed for an average of 22 months found no increase in the overall cancer rate compared to patients treated with disease-modifying anti-rheumatic drugs (DMARDs) [137].

C Tarella et al. [138] described the long-term outcome of a large series of patients with lymphoma who received an intensive chemotherapy schedule, with or without addition of four to six doses of rituximab. In this study, rituximab addition was associated with an increased risk of solid tumor occurrence both in univariate and multivariate analysis. Conversely, rituximab had a significant protective role on the risk of death. This finding in lymphoma patients is noteworthy and should be further explored. Caution is therefore also warranted in other disease backgrounds. The different patient background and the combination of rituximab with particular anticancer drugs in the lymphoma population, however, precludes simple extrapolation of the data from the lymphoma population to the IMID field.

Abatacept

Abatacept is a fusion protein of IgG and the extracellular domain of CTLA-4 that inhibits T cell activation approved for treatment of moderate to severe RA [139]. An integrated analysis of five registries comprising 4134 RA patients found similar overall rates of cancer in patients treated with abatacept as in the general RA population [140]. A long-term extension of an RCT with a five-year follow-up period, showed no increased malignancy rates under abatacept treatment [141].

Ustekinumab

Ustekinumab is a blocking antibody to the IL-12/IL-23 receptor approved for the treatment of plaque psoriasis [142]. Cumulative safety data from four phase II and III studies including 3117 patients shows no increase in malignancy rate during the first four years of ustekinumab treatment [143].

Anakinra

Anakinra is a competitive inhibitor of IL-1 binding to the IL-1 receptor approved for the treatment of RA [144]. Prospective observational data from the German database RABBIT demonstrated no increase in the overall cancer rate in RA patients treated with anakinra [145].

Tocilizumab

Tocilizumab is a humanized mouse monoclonal antibody to the IL-6 receptor that blocks ligand binding [146][133]. A 2010 meta-analysis and systematic review of randomized clinical trials found that tocilizumab does not significantly increase the rate of malignancies [127].

Biologics in patients with cancer history

A 2010 study of data from the British Society for Rheumatology Biologics Register reported that in patients with RA, prior malignancy and an average of three years of follow up, the malignancy incidence rate did not increase in patients receiving anti-TNF therapy [147]. The authors concluded that the way in which the patients were selected for anti-TNF therapy is not leading to an increased risk of incident malignancy but cautioned against concluding that it is safe to use anti-TNF biologics for RA patients with prior malignancy.

Up to now there is no clear evidence to guide the decision whether or not to use immunosuppressants or biologics in patients with previous history of cancer. Treatment decisions in these patients must taken on a case-by-case basis after discussion with a multidisciplinary team, taking into account the need for such treatment, the risk of cancer recurrence and the sensitivity of a specific cancer to immunosuppression, finally weighing benefits versus risks for the patient.

Conclusion

The evidence provided in this manuscript leads to the conclusion that some IMIDs are associated with an increased cancer risk and that the cancer risk associated with immunotherapy should be discussed in relation with each individual conventional or biological drug.

Overall cancer incidence and mortality risk are similar to the general population in IBD, and slightly increased for RA and psoriasis.

RA entails a twofold increase in lymphoma risk and an increased risk for lung cancer. Anti-TNF treatment of RA does not increase overall cancer risk, but increases the risk of NMSC, especially when combined with methotrexate.

In IBD, overall cancer risk is elevated in CD but not in UC. IBD patients run an increased risk for gastrointestinal malignancies driven by chronic intestinal inflammation. Thiopurines increase the risk for NMSC, while limited data are available on the effect of anti-TNF treatment on cancer risk in IBD.

Psoriasis increases the risk for some cancers, such as NMSC and alcohol or smoking-related tumors. Higher cancer risks in patients with severe psoriasis may be confounded by the effect of systemic treatment. PUVA, cyclosporine and anti-TNFs increase NMSC risk in psoriasis patients.

Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce.

Abbreviations

CD:

Crohn’s disease

IBD:

Inflammatory bowel disease

IL:

Interleukin

IMID:

Immune-mediated inflammatory disease

MHC:

Major Histocompatibility complex

NMSC:

Non-melanoma skin cancer

PUVA:

Psoralen – Ultraviolet A

RA:

Rheumatoid arthritis

SLE:

Systemic Lupus erythematosus

TNF:

Tumor necrosis factor

UC:

Ulcerative colitis.

References

  1. 1.

    Williams JP, Meyers JA: Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care. 2002, 8 (21 Suppl): S664-S681. quiz S682–5

  2. 2.

    Mantovani A: Cancer: Inflaming metastasis. Nature. 2009, 457: 36-37.

  3. 3.

    Grivennikov SI, Karin M: Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev. 2010, 20: 65-71.

  4. 4.

    Solinas G, Germano G, Mantovani A, Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009, 86: 1065-1073.

  5. 5.

    Burnet FM: Immunological surveillance in neoplasia. Transplant Rev. 1971, 7: 3-25.

  6. 6.

    Bui JD, Schreiber RD: Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Curr Opin Immunol. 2007, 19: 203-208.

  7. 7.

    Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol. 2004, 22: 329-360.

  8. 8.

    Nakachi K, Hayashi T, Imai K, Kusunoki Y: Perspectives on cancer immuno-epidemiology. Cancer Sci. 2004, 95: 921-929.

  9. 9.

    Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001, 410: 1107-1111.

  10. 10.

    Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI: Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000, 191: 661-668.

  11. 11.

    Street SEA, Trapani JA, MacGregor D, Smyth MJ: Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon. J Exp Med. 2002, 196: 129-134.

  12. 12.

    Engel AM, Svane IM, Rygaard J, Werdelin O: MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol. 1997, 45: 463-470.

  13. 13.

    Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O: Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol. 1996, 26: 1844-1850.

  14. 14.

    Müller-Hermelink N, Braumüller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Förster I, Huss R, Weber WA, Kneilling M, Röcken M: TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell. 2008, 13: 507-518.

  15. 15.

    Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454: 436-444.

  16. 16.

    Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357: 539-545.

  17. 17.

    Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005, 5: 749-759.

  18. 18.

    Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JFF, Wilson M, Mehta Z, Meade TW: Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012, 379: 1602-1612.

  19. 19.

    Jacobs EJ, Newton CC, Gapstur SM, Thun MJ: Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst. 2012, 104: 1208-1217.

  20. 20.

    Baron JA: Aspirin and cancer: trials and observational studies. J Natl Cancer Inst. 2012, 104: 1199-1200.

  21. 21.

    Pasche B: Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA. 2013, 309: 2598-2599.

  22. 22.

    Kaiser J: Will an aspirin a day keep cancer away?. Science. 2012, 337: 1471-1473.

  23. 23.

    Zumsteg A, Christofori G: Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol. 2009, 21: 60-70.

  24. 24.

    Zamarron BF, Chen W: Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011, 7: 651-658.

  25. 25.

    Pastuła A, Marcinkiewicz J: Myeloid-derived suppressor cells: a double-edged sword?. Int J Exp Pathol. 2011, 92: 73-78.

  26. 26.

    Ben-Neriah Y, Karin M: Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011, 12: 715-723.

  27. 27.

    Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997, 336: 1066-1071.

  28. 28.

    Hayden MS, Ghosh S: NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26: 203-234.

  29. 29.

    Karin M, Cao Y, Greten FR, Li Z-W: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2: 301-310.

  30. 30.

    Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005, 64: 1414-1420.

  31. 31.

    Zhang J, Wu P, Hu Y: Clinical and marketed proteasome inhibitors for cancer treatment. Curr Med Chem. 2013, 20: 2537-2551.

  32. 32.

    Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005, 64: 1421-1426.

  33. 33.

    Smitten AL, Simon TA, Hochberg MC, Suissa S: A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008, 10: R45-

  34. 34.

    Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006, 54: 692-701.

  35. 35.

    Loftus EV: Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004, 126: 1504-1517.

  36. 36.

    Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR: Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010, 95: 1216-1220.

  37. 37.

    Watanabe T, Soga K, Hirono H, Hasegawa K, Shibasaki K, Kawai H, Aoyagi Y: Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J Gastroenterol. 2009, 15: 231-239.

  38. 38.

    Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C: Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci. 2011, 56: 578-585.

  39. 39.

    Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Jewell D: Cancer in patients with ulcerative colitis, Crohn’s disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol. 2008, 20: 297-304.

  40. 40.

    Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM: Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer. 2011, 117: 1163-1171.

  41. 41.

    Silano M, Volta U, Mecchia AM, Dessì M, Di-Benedetto R, De-Vincenzi M: Delayed diagnosis of coeliac disease increases cancer risk. BMC Gastroenterol. 2007, 7: 8-

  42. 42.

    Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T: Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010, 105: 1480-1487.

  43. 43.

    Laukoetter MG, Mennigen R, Hannig CM, Osada N, Rijcken E, Vowinkel T, Krieglstein CF, Senninger N, Anthoni C, Bruewer M: Intestinal cancer risk in Crohn’s disease: a meta-analysis. J Gastrointest Surg. 2011, 15: 576-583.

  44. 44.

    Canavan C, Abrams KR, Mayberry J: Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006, 23: 1097-1104.

  45. 45.

    Hemminki K, Li X, Sundquist J, Sundquist K: Cancer risks in Crohn disease patients. Ann Oncol. 2009, 20: 574-580.

  46. 46.

    Szekanecz Z, Szekanecz E, Bakó G, Shoenfeld Y: Malignancies in autoimmune rheumatic diseases - a mini-review. Gerontology. 2011, 57: 3-10.

  47. 47.

    Prizment AE, Alonso A, Folsom AR, Ahmed RL, Virnig BA, Warshaw EM, Anderson KE: Association between psoriasis and incident cancer: the Iowa’s Women’s Health Study. Cancer Causes Control. 2011, 22: 1003-1010.

  48. 48.

    Hannuksela-Svahn A, Pukkala E, Läärä E, Poikolainen K, Karvonen J: Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol. 2000, 114: 587-590.

  49. 49.

    Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL: The risk of malignancy associated with psoriasis. Arch Dermatol. 2001, 137: 778-783.

  50. 50.

    Chen Y-J, Wu C-Y, Chen T-J, Shen J-L, Chu S-Y, Wang C-B, Chang Y-T: The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol. 2011, 65: 84-91.

  51. 51.

    Lanoy E, Engels EA: Skin cancers associated with autoimmune conditions among elderly adults. Br J Cancer. 2010, 103: 112-114.

  52. 52.

    Boffetta P, Gridley G, Lindelöf B: Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol. 2001, 117: 1531-1537.

  53. 53.

    Ji J, Shu X, Sundquist K, Sundquist J, Hemminki K: Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer. 2009, 100: 1499-1502.

  54. 54.

    Söderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M: Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case–control study in Sweden. Eur J Cancer. 2006, 42: 3028-3033.

  55. 55.

    Gelfand JM, Berlin J, Van-Voorhees A, Margolis DJ: Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol. 2003, 139: 1425-1429.

  56. 56.

    Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard M, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le-Maître M, Ortonne J-P, Paul C: Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013, 27 (Suppl 3): 36-46.

  57. 57.

    Richard M, Barnetche T, Horreau C, Brenaut E, Pouplard C, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le-Maître M, Misery L, Ortonne J-P, Paul C: Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol. 2013, 27 (Suppl 3): 2-11.

  58. 58.

    Askling J, Brandt L, Lapidus A, Karlén P, Björkholm M, Löfberg R, Ekbom A: Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005, 54: 617-622.

  59. 59.

    Boffetta P, Rabkin CS, Gridley G: A cohort study of cancer among sarcoidosis patients. Int J Cancer. 2009, 124: 2697-2700.

  60. 60.

    Liu H, Ding Q, Yang K, Zhang T, Li G, Wu G: Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia. Rheumatology (Oxford). 2011, 50: 343-348. 10.1093/rheumatology/keq304.

  61. 61.

    Chen Y-J, Chang Y-T, Wang C-B, Wu C-Y: Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med. 2010, 123: 1150-1156.

  62. 62.

    Kiss E, Kovacs L, Szodoray P: Malignancies in systemic lupus erythematosus. Autoimmun Rev. 2010, 9: 195-199.

  63. 63.

    Rosenthal AK, McLaughlin JK, Gridley G, Nyrén O: Incidence of cancer among patients with systemic sclerosis. Cancer. 1995, 76: 910-914.

  64. 64.

    Magruder JT, Elahi D, Andersen DK: Diabetes and pancreatic cancer: chicken or egg?. Pancreas. 2011, 40: 339-351.

  65. 65.

    Stevens RJ, Roddam AW, Beral V: Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007, 96: 507-509.

  66. 66.

    Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002, 56: 48-54.

  67. 67.

    Veloso FT: Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome?. World J Gastroenterol. 2011, 17: 2702-2707.

  68. 68.

    Bernstein CN, Blanchard JF, Kliewer E, Wajda A: Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001, 91: 854-862.

  69. 69.

    Thomas T, Abrams KA, Robinson RJ, Mayberry JF: Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007, 25: 657-668.

  70. 70.

    Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A: Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004, 53: 1813-1816.

  71. 71.

    Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T: Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007, 133: 1099-1105. quiz 1340–1

  72. 72.

    Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med. 2009, 361: 496-509.

  73. 73.

    El-Gabalawy H, Guenther LC, Bernstein CN: Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010, 85 (Imid): 2-10.

  74. 74.

    Naldi L: Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. 2010, 28: 88-92.

  75. 75.

    Patel RV, Clark LN, Lebwohl M, Weinberg JM: Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009, 60: 1001-1017.

  76. 76.

    Stern RS: Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol. 2006, 142: 1132-1135.

  77. 77.

    Väkevä L, Reitamo S, Pukkala E, Sarna S, Ranki A: Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol. 2008, 88: 117-120.

  78. 78.

    Lee H-M, Sugino H, Nishimoto N: Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol. 2010, 2010: 676284-

  79. 79.

    Smith PP, Gordon C: Systemic lupus erythematosus: clinical presentations. Autoimmun Rev. 2010, 10: 43-45.

  80. 80.

    Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE: Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer. 2011, 104: 1478-1481.

  81. 81.

    Dinarello CA: Anti-inflammatory Agents: Present and Future. Cell. 2010, 140: 935-50.

  82. 82.

    Martinez OM, De-Gruijl FR: Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant. 2008, 8: 2205-2211.

  83. 83.

    Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res. 1970, 13: 1-27.

  84. 84.

    Burnet FM: Implications of immunological surveillance for cancer therapy. Isr J Med Sci. 1971, 7: 9-16.

  85. 85.

    Karran P, Attard N: Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008, 8: 24-36.

  86. 86.

    Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009, 374: 1617-1625.

  87. 87.

    Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD: Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010, 8: 268-274.

  88. 88.

    Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005, 54: 1121-5.

  89. 89.

    Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R: Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol. 2012, 27: 385-389.

  90. 90.

    Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume J-C, Lamarque V, Dubertret L: Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003, 120: 211-216.

  91. 91.

    Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H: Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007, 41: 21-28.

  92. 92.

    Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, Harkness A, Lewis D, Littlejohn G, Miller MH, Ryan PFJ, Jolley D: Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008, 59: 794-799.

  93. 93.

    Salliot C, van der-Heijde D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009, 68: 1100-1104.

  94. 94.

    Krathen MS, Gottlieb AB, Mease PJ: Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol. 2010, 37: 2205-2215.

  95. 95.

    Brodsky RA: High dose cyclophosphamide treatment for autoimmune disorders. Sci World J. 2002, 2: 1808-15.

  96. 96.

    Vlaovic P, Jewett MAS: Cyclophosphamide-induced bladder cancer. Can J Urol. 1999, 6: 745-748.

  97. 97.

    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975, 72: 3666-3670.

  98. 98.

    Fiers W, Beyaert R, Brouckaert P, Everaerdt B, Haegeman C, Suffys P, Tavernier J, Vanhaesebroeck B: TNF: its potential as an antitumour agent. Dev Biol Stand. 1988, 69: 143-151.

  99. 99.

    Van-Horssen R, Ten-Hagen TLM, Eggermont AMM: TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006, 11: 397-408.

  100. 100.

    Balkwill F: Tumour necrosis factor and cancer. Nat Rev Cancer. 2009, 9: 361-371.

  101. 101.

    Cantaert T, Baeten D, Tak PP, Van-Baarsen LGM: Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther. 2010, 12: 219-

  102. 102.

    Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008, 117: 244-279.

  103. 103.

    Wei Y, Liu F, Li B, Chen X, Ma Y, Yan L, Wen T, Xu M, Wang W, Yang J: Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci. 2011, 56: 2227-2236.

  104. 104.

    Yang Y, Luo C, Feng R, Bi S: The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011, 137: 947-952.

  105. 105.

    Guo YM, Yu WW, Shen XZ: Tumor necrosis factor rs361525 (−238G > A) polymorphism contributes to hepatocellular carcinoma susceptibility. Saudi Med J. 2010, 31: 1101-1105.

  106. 106.

    Guo Y-M, Wei W-Y, Shen X-Z: Tumour necrosis factor 308 polymorphisms and hepatocellular carcinoma risk: a meta-analysis. Hepatogastroenterology. 2010, 57: 926-31.

  107. 107.

    Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, De-Sanjosé S, Hughes AM, Cerhan JR, Skibola DR, Purdue M, Kane E, Lan Q, Foretova L, Schenk M, Spinelli JJ, Slager SL, De-Roos AJ, Smith MT, Roman E, Cozen W, Boffetta P, Kricker A, Zheng T, Lightfoot T, Cocco P, Benavente Y, Zhang Y, Hartge P, Linet MS, Becker N, Brennan P: Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol. 2010, 171: 267-276.

  108. 108.

    Fang F, Yao L, Yu XJ, Yu L, Wu Q, Yu L: TNFalpha −308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10, 184 cases and 12, 911 controls. Breast Cancer Res Treat. 2010, 122: 267-271.

  109. 109.

    Zhang J, Dou C, Song Y, Ji C, Gu S, Xie Y, Mao Y: Polymorphisms of tumor necrosis factor-alpha are associated with increased susceptibility to gastric cancer: a meta-analysis. J Hum Genet. 2008, 53: 479-489.

  110. 110.

    Taylor PC: Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 2010, 10: 308-315.

  111. 111.

    Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR: TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol. 2008, 126: 13-30.

  112. 112.

    Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F: The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology. 1999, 117: 1433-1437.

  113. 113.

    Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002, 46: 3151-3158.

  114. 114.

    Alcaín G, Andrade RJ, Queipo de Llano MP, Moreno MJ, García-Cortés M, Franquelo E: Acute leukemia after infliximab therapy. Am J Gastroenterol. 2003, 98: 2577-

  115. 115.

    Bakland G, Nossent H: Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford). 2003, 42: 900-901. 10.1093/rheumatology/keg128.

  116. 116.

    Wolfe F, Michaud K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients. Arthritis Rheum. 2004, 50: 1740-1751.

  117. 117.

    Wolfe F, Michaud K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007, 56: 2886-2895.

  118. 118.

    Wolfe F, Michaud K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89, 710 person-years of observation. Arthritis Rheum. 2007, 56: 1433-1439.

  119. 119.

    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006, 295: 2275-2285.

  120. 120.

    Peyrin-Biroulet L, Deltenre P, De-Suray N, Branche J, Sandborn WJ, Colombel J-F: Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008, 6: 644-653.

  121. 121.

    Leombruno JP, Einarson TR, Keystone EC: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009, 68: 1136-1145.

  122. 122.

    Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ: Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009, 68: 1177-1183.

  123. 123.

    Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009, 7: 874-881.

  124. 124.

    Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, Van-Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P: Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011, 70: 1895-1904.

  125. 125.

    Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM: The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011, 64: 1035-1050.

  126. 126.

    Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D: Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011, 20: 119-130.

  127. 127.

    Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJK: Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011, 50: 552-562. 10.1093/rheumatology/keq343.

  128. 128.

    Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME: Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012, 308: 898-908.

  129. 129.

    Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc J-L, Lapeyre-Mestre M: Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses. PLoS One. 2012, 7: e48991-

  130. 130.

    Askling J, Van-Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L: Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum. 2009, 60: 3180-3189.

  131. 131.

    Singh JA, Noorbaloochi S, Singh G: Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010, CD008341-10.1002/14651858.CD008341.

  132. 132.

    Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P: Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010, 69: 400-408.

  133. 133.

    Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED: T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013, 108: 99-105.

  134. 134.

    Dunn LK, Feldman SR: Alefacept treatment for chronic plaque psoriasis. Skin Therapy Lett. 2010, 15: 1-3.

  135. 135.

    Goffe B, Papp K, Gratton D, Krueger GG, Darif M, Lee S, Bozic C, Sweetser MT, Ticho B: An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther. 2005, 27: 1912-1921.

  136. 136.

    Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, Proudlove C, Kennedy T, Moots R, Williamson P, Dickson R: Rituximab for the treatment of rheumatoid arthritis. Health Technol Assess. 2009, 13 (Suppl 2): 23-29.

  137. 137.

    Slimani S, Lukas C, Combe B, Morel J: Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine. 2011, 78: 484-487.

  138. 138.

    Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di-Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A: Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011, 29: 814-824.

  139. 139.

    Buch MH, Vital EM, Emery P: Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2008, 10 (Suppl 1): S5-

  140. 140.

    Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F, Hochberg MC, Qi K, Suissa S: Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis. 2009, 68: 1819-1826.

  141. 141.

    Genovese MC, Schiff M, Luggen M, Le-Bars M, Aranda R, Elegbe A, Dougados M: Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol. 2012, 39: 1546-1554.

  142. 142.

    Gandhi M, Alwawi E, Gordon KB: Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg. 2010, 29: 48-52.

  143. 143.

    Reich K, Papp KA, Griffiths CEM, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu M-C, Lebwohl M, Gordon KB: An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012, 11: 300-312.

  144. 144.

    Kary S, Burmester GR: Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int J Clin Pract. 2003, 57: 231-234.

  145. 145.

    Strangfeld A, Hierse F, Rau R, Burmester G-R, Krummel-Lorenz B, Demary W, Listing J, Zink A: Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010, 12: R5-

  146. 146.

    Venkiteshwaran A: Tocilizumab. MAbs. 2009, 1: 432-8.

  147. 147.

    Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DPM: Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2010, 62: 755-763. 10.1002/acr.20129.

Download references

Acknowledgements

This work was written following the Spring Lecture Sessions on cancer and immune mediated inflammatory disorders of the Academy of Immunology for Clinicians – Belgium and supported by an unrestricted educational grant from Abbott. Rudi Beyaert is supported by grants from the “Belgian Foundation against Cancer”, “IAP”, “FWO”, “IWT”, and the “Hercules Foundation”, “GOA” and “Group-ID MRP” initiatives of the Ghent University. The authors acknowledge the medical writing contributions of Veerle Persy, MD, PhD (Hugin Mugin Research) and Phil Leventhal, PhD (4Clinics).

Author information

Correspondence to Filip De Keyser.

Additional information

Competing interests

Laurent Beaugerie served as a speaker for Abbott, Ferring and Merck, served as consultant for Abbott.

Lieve Brochez served as speaker for Abbott and Pfizer.

Manuelle Viguier served as speaker for Abbott, Pfizer and Janssen-Cilag.

P Masson served as speaker for Abbott.

E Louis received research support from Abbott, MSD/Schering Plough, AstraZeneca; served as speaker for Abbott, AstraZeneca, Ferring, Falk, MSD/Schering Plough, Menarini, Movetis, Nycomed; and served as consultant for Abbott, AstraZeneca, MSD/Schering Plough, Millenium, Ferring, Shire.

F De Keyser received research support from Roche, UCB, Actelion; served as consultant for MSD/Schering Plough, Abbott, UCB, Roche.

Authors’ contributions

FDK, EL and PM organized the AIC Spring Lectures and took the initiative to turn their content into a review article. All authors participated in designing the content and setup of the manuscript. R.B performed literature search and data retrieval on the relationship between inflammation and cancer. FDK created the content of the risk of cancer in RA; LB, GVA and EL were responsible for the part on IBD and cancer, MV and LB reviewed the literature on psoriasis and cancer. JCR, VC, GJ, JPM, HP contributed the oncology expert point of view on cancer risk in IMID patients and reviewed the literature on risk of biological treatment in patients with a history of cancer. All authors read and approved the final manuscript.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Beyaert, R., Beaugerie, L., Van Assche, G. et al. Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer 12, 98 (2013) doi:10.1186/1476-4598-12-98

Download citation

Keywords

  • Antirheumatic agents
  • Autoimmune diseases
  • Biological products
  • Cancer
  • Inflammation
  • Tumor necrosis factor